newsfilter
← Latest News
GlobeNewswire·

Rein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary Fibrosis

FDA lifts clinical hold following review of Company's Complete Response submission.Company expects to restart U.S. enrollment in late 2025 or early 2026 across 20 clinical sites.Early data suggests that LTI-03 may not